Novavax investor Shah Capital pushes for board shakeup
By Michael Erman & Sriparna Roy
Shah Capital nominates two highly qualified independent director candidates for Novavax
Novavax failed to capitalize on fears surrounding mRNA vaccines, activist investor says
By Louis Goss
Novavax (NASDAQ:NVAX) Jumps Amid Activist Investor Push - TipRanks.com
By Kailas Salunkhe
Hedge fund urges board shake-up at Novavax over struggling Covid vaccine
By Oliver Barnes
Full Coverage of this story
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street
By Adria Cimino
Analysis finds positive risk-benefit for Novavax COVID vaccine
By Lisa Schnirring
Stocks making the biggest moves midday: NVDA, RIVN, MRNA, NVAX
By Lisa Kailai Han
Better Bull Market Buy: Novavax vs. Pfizer
By Keith Speights & Adria Cimino
Short Sellers Are Betting Against Novavax (NVAX) Stock
By Dana Blankenhorn
Novavax posts surprise quarterly profit as company prepares to launch new Covid vaccine
By Annika Kim Constantino
Better Recovery Story Buy: Novavax vs. Teladoc
By Adria Cimino
Novavax stock jumps after company settles dispute over canceled Covid vaccine purchase
By Annika Kim Constantino
Novavax forecasts higher-than-expected revenue; shares surge
By Michael Erman & Bhanvi Satija
Is Novavax, the latecomer COVID vaccine, worth the wait?
By Danielle E. Gaines
Vaccine maker Novavax tops revenue estimates, eyes more cost cuts
By Patrick Wingrove & Bhanvi Satija
Novavax's updated Covid vaccine can still catch up to Pfizer, Moderna shots this fall
By Annika Kim Constantino
Week in Review: Novo Nordisk Riding High, Novavax in the Black (For Now), Nektar Sues Lilly and More
By Greg Slabodkin
Biden administration asks Pfizer, Moderna and Novavax for 'reasonable' prices on updated Covid vaccines
By Annika Kim Constantino
Novavax stock spikes 29% after company snags $350 million from Canada for unused Covid shots
By Annika Kim Constantino
Novavax's CEO promises a turnaround & how Lilly roiled the obesity market
By Adam Feuerstein, Damian Garde & Meg Tirrell
Novavax Expects Its Updated COVID-19 Vaccine Candidate to Work on Circulating Variants
By Cecelia Smith-Schoenwalder
Novavax bosses cash out for $46 million with COVID-19 vaccine trials still under way
By Jessica DiNapoli
Don't count us out yet, Novavax says
By Tina Reed
Three immunizations with Novavax's protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2 | npj Vaccines
By Daniel J Sheward, Gale Smith & Karin Loré
Opinion | Responding to reader questions about this fall’s covid vaccine
Opinion
By Leana Wen
Novavax pulling out all the stops to ensure successful season with updated protein-based COVID-19 vaccine
By Guy Martin
Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting Demand
By Robert Hart
Novavax says new COVID shot now available in U.S. pharmacies
By Arun Koyyur & Christy Santhosh
Europe to decide on Novavax's COVID vaccine in October
By Michael Erman, Kalluvila Sriraj & Bhanvi Satija